Skip to main content

Advertisement

SpringerLink
Log in

Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759–772

    Article  CAS  PubMed  Google Scholar 

  2. Fisher R, DeAngelis LM (2010) Leptomeningeal metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1000–1007

    Google Scholar 

  3. Fuchs IB, Loebbecke M, Buhler H et al (2002) HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20(19):4130–4133

    Article  PubMed  Google Scholar 

  4. Johnson ML, Nehhozina T, Conlin AK et al (2008) Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): tissue microarray (TMA) studies. J Clin Oncol 26(May 20 suppl):abstract 1039

    Google Scholar 

  5. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13(7):1036–1043

    Article  CAS  PubMed  Google Scholar 

  6. MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26(May 20 suppl):Abstract 1000

  7. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953–1958

    Article  CAS  PubMed  Google Scholar 

  8. Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7):1938–1946

    Article  CAS  PubMed  Google Scholar 

  9. Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10(1):R20

    Article  PubMed  Google Scholar 

  10. Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977

    Article  PubMed  Google Scholar 

  11. Brufsky AM, Mayer M, Rugo HS et al (2008) RegistHER: patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. In: ASCO Breast cancer symposium, 2008, p Abstract 89, Washington, D.C., 2008

  12. Altundag K, Bondy ML, Mirza NQ et al (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640–2647

    Article  CAS  PubMed  Google Scholar 

  13. Lamovec J, Bracko M (1991) Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48(1):28–33

    Article  CAS  PubMed  Google Scholar 

  14. Bidard FC, Guilhaume MN, Gauthier H, Cottu PH, Dieras V, Pierga JY (2009) Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 93(2):287–288

    Article  CAS  PubMed  Google Scholar 

  15. Gauthier H, Guilhaume M-N, Bidard FC et al (2009) Meningeal carcinomatosis in patients with breast cancer: clinical features and prognostic factors in 91 patients from a single institution. Cancer Res 69(Suppl):abstract 1090

    Google Scholar 

  16. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638–2645

    Article  PubMed  Google Scholar 

  17. Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15(5):1373–1377

    CAS  PubMed  Google Scholar 

  18. Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anti-cancer drugs 19(8):832–836

    Article  CAS  PubMed  Google Scholar 

  19. Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7(9):778–780

    Article  PubMed  Google Scholar 

  20. Siderov J (2006) Care with intrathecal trastuzumab. Lancet Oncol 7(11):888

    Article  PubMed  Google Scholar 

  21. Tham YL, Hinckley L, Teh BS, Elledge R (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7(2):164–166

    Article  PubMed  Google Scholar 

  22. Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16(1):88–92

    Article  PubMed  Google Scholar 

  23. Lin NU, Dieras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459

    Article  CAS  PubMed  Google Scholar 

  24. Boccardo F, Kaufman B, Baselga J et al (2008) Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastses (BM) from HER2 + breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). J Clin Oncol 26:abstract 1094

    Google Scholar 

  25. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043

    Article  CAS  PubMed  Google Scholar 

  26. Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82(8):1513–1520

    Article  CAS  PubMed  Google Scholar 

  27. Shattuck DL, Miller JK, Carraway KL III, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68(5):1471–1477

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

The author discloses the following conflicts:

Genentech: research funding for clinical trials (no direct salary support; Consultant <$10 K).

GlaxoSmithKline: research funding for clinical trials (no direct salary support; Consultant <$10 K).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA

    Nancy U. Lin

Authors
  1. Nancy U. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy U. Lin.

Additional information

This is an invited commentary to article doi:10.1007/s10549-009-0627-3.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, N.U. Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?. Breast Cancer Res Treat 123, 129–131 (2010). https://doi.org/10.1007/s10549-009-0720-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0720-7

Keywords

Search

Navigation